Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BEAM
BEAM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BEAM News
FDA Approves BEAM-304 for Transformative PKU Therapy Development
2d ago
Newsfilter
Beam Therapeutics Receives FDA Clearance for Gene-Editing Therapy
1d ago
NASDAQ.COM
Avaí Bio Achieves Milestone in α-Klotho Cell Bank Development
May 28 2026
Newsfilter
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam
May 26 2026
Fool
Analysis of Gene Editing Industry Prospects
May 26 2026
NASDAQ.COM
ADAR1 Capital Management Acquires Stake in Beam Therapeutics
May 18 2026
Fool
AlphaDetect Partners with Beam Therapeutics to Enhance Alpha-1 Detection Efforts
May 13 2026
Newsfilter
AlphaDetect Partners with Beam Therapeutics to Enhance Detection Efforts
May 13 2026
PRnewswire
Beam Therapeutics Presents Updated Data on Risto-cel for Sickle Cell Disease
May 12 2026
Newsfilter
Jim Cramer's Insights on Multiple Stocks
Apr 29 2026
CNBC
Jim Cramer's Insights on Various Stocks
Apr 28 2026
CNBC
Gene Drive Technology as a Solution to Invasive Species
Apr 12 2026
Yahoo Finance
Beam Therapeutics CEO John Evans Sells Shares Amid Positive Clinical Data
Apr 11 2026
NASDAQ.COM
Beam Therapeutics CEO Sells Shares Amid Positive Clinical Data
Apr 11 2026
Fool
Beam's Therapy Shows Promising Efficacy for Sickle Cell Disease
Apr 02 2026
stocktwits
Risto-cel Clinical Data Significantly Improves Sickle Cell Disease Outcomes
Apr 01 2026
Newsfilter
Show More News
